Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Website: instilbio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -13.5% (LTM)

Entry Point: Share price is 9 938.0% higher than minimum and 62.5% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: TIL
Share price, USD:  (-1.7%)31.69
year average price 25.05  


year start price 12.53 2024-07-28

min close price 10.06 2024-08-16

max close price 84.52 2024-09-13

current price 31.69 2025-07-27
Common stocks: 130 079 097

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 4 122
Net Debt ($m): -53
EV (Enterprise Value): 4 069
Price to Book: 23.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-02globenewswire.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

2025-05-25seekingalpha.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

2025-03-04globenewswire.com

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

2024-11-05globenewswire.com

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

2024-09-16zacks.com

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

2024-09-14fool.com

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

2024-09-13seekingalpha.com

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

2024-08-13globenewswire.com

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

2024-08-01globenewswire.com

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

2024-03-27Zacks Investment Research

What Makes Instil Bio (TIL) a New Buy Stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-08-13 2024-05-10 2024-03-21 2023-11-13 2023-08-14 2023-05-11 2023-03-31 2022-11-14 2022-08-12
acceptedDate 2024-11-13 07:39:58 2024-08-13 17:16:42 2024-05-10 07:10:33 2024-03-21 17:05:50 2023-11-13 17:03:23 2023-08-14 07:05:14 2023-05-11 07:09:31 2023-03-31 07:38:45 2022-11-14 16:17:06 2022-08-12 07:23:11
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 8M 0 0 0 0 0 0
costOfRevenue 0 1 000 000 993 000 1M 953 000 835 000 0 0 0 0
grossProfit 0 -1 000 000 -993 000 7M -953 000 -835 000 0 0 0 0
grossProfitRatio 0 0 0 0.865 0 0 0 0 0 0
researchAndDevelopmentExpenses 10M 3M 7M 2M 8M 8M 21M 21M 40M 42M
generalAndAdministrativeExpenses 11M 11M 12M 11M 12M 12M 13M 13M 17M 17M
sellingAndMarketingExpenses 0 0 -993 000 -1M 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 11M 11M 11M 10M 12M 12M 13M 13M 17M 17M
otherExpenses 3M -1 000 000 -428 000 -120 000 46M 628 000 -57 000 1M 0 0
operatingExpenses 24M 13M 19M 12M 67M 20M 34M 34M 57M 59M
costAndExpenses 24M 14M 20M 13M 67M 20M 34M 34M 57M 59M
interestIncome 2M 2M 2M 2M 2M 2M 2M 2M 1M 486 000
interestExpense 2M 2M 2M 2M -2M 590 000 636 000 745 000 807 000 331 000
depreciationAndAmortization 901 000 1 000 000 993 000 1M 953 000 991 000 28M 26M 3M 1M
ebitda -20M -12M -19M -12M -67M -17M -30M -31M -54M -58M
ebitdaratio 0 0 0 -1.541 0 0 0 0 0 0
operatingIncome -24M -14M -20M -13M -67M -21M -58M -57M -57M -59M
operatingIncomeRatio 0 0 0 -1.676 0 0 0 0 0 0
totalOtherIncomeExpensesNet 610 000 -1M -5M -70 000 -716 000 -382 000 1M 2M 54 000 -877 000
incomeBeforeTax -23M -15M -24M -13M -67M -19M -57M -54M -57M -60M
incomeBeforeTaxRatio 0 0 0 -1.685 0 0 0 0 0 0
incomeTaxExpense 0 0 949 724 1M -953 000 227 000 -742 000 -605 000 -371 000 -609 000
netIncome -23M -15M -24M -13M -67M -19M -56M -54M -56M -59M
netIncomeRatio 0 0 0 -1.685 0 0 0 0 0 0
eps -3.54 -2.29 -3.74 -1.99 -10.37 -0.14 -0.43 -0.41 -0.43 -0.46
epsdiluted -3.54 -2.29 -3.74 -1.99 -10.37 -0.14 -0.43 -0.41 -0.43 -0.46
weightedAverageShsOut 7M 7M 7M 7M 7M 130M 130M 130M 130M 129M
weightedAverageShsOutDil 7M 7M 7M 7M 7M 130M 130M 130M 130M 129M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-08-13 2024-05-10 2024-03-21 2023-11-13 2023-08-14 2023-05-11 2023-03-31 2022-11-14 2022-08-12
acceptedDate 2024-11-13 07:39:58 2024-08-13 17:16:42 2024-05-10 07:10:33 2024-03-21 17:05:50 2023-11-13 17:03:23 2023-08-14 07:05:14 2023-05-11 07:09:31 2023-03-31 07:38:45 2022-11-14 16:17:06 2022-08-12 07:23:11
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 7M 7M 5M 11M 9M 22M 27M 44M 41M 42M
shortTermInvestments 114M 142M 148M 141M 174M 180M 196M 217M 262M 312M
cashAndShortTermInvestments 120M 149M 154M 152M 183M 203M 223M 261M 303M 355M
netReceivables 3M 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 12M 6M 7M 9M 11M 12M 9M 8M 10M 13M
totalCurrentAssets 133M 155M 161M 161M 196M 221M 240M 269M 314M 368M
propertyPlantEquipmentNet 131M 135M 136M 141M 142M 185M 183M 209M 198M 181M
goodwill 0 0 0 0 0 0 0 0 6M 6M
intangibleAssets 0 0 0 0 0 0 0 0 10M 10M
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 16M 16M
longTermInvestments 3M 4M 8M 23M 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 6M 581 000 2M 639 000 3M 3M 4M 3M 5M 4M
totalNonCurrentAssets 140M 139M 145M 165M 145M 188M 187M 213M 219M 201M
otherAssets 0 0 0 0 0 0 0 0 0 0
totalAssets 273M 294M 306M 326M 340M 408M 427M 482M 533M 569M
accountPayables 1M 1M 1M 1M 2M 2M 1M 2M 5M 6M
shortTermDebt 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 10M 14M 0 0 0 0
otherCurrentLiabilities 7M 7M 8M 8M 324 000 459 000 23M 28M 34M 35M
totalCurrentLiabilities 10M 10M 11M 11M 13M 18M 27M 33M 42M 43M
longTermDebt 84M 84M 82M 81M 84M 85M 81M 78M 69M 55M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 555 000 1M
otherNonCurrentLiabilities 2M 5M 7M 8M 8M 8M 8M 8M 72M 11M
totalNonCurrentLiabilities 86M 89M 89M 89M 93M 93M 89M 86M 80M 67M
otherLiabilities 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 3M 4M 2M 3M 5M 6M 6M 8M 8M 8M
totalLiabilities 96M 99M 100M 100M 106M 112M 116M 119M 122M 110M
preferredStock 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0 0
retainedEarnings -643M -620M -605M -581M -568M -501M -482M -425M -371M -315M
accumulatedOtherComprehensiveIncomeLoss -520 000 -627 000 -563 000 -348 000 -525 000 -795 000 -406 000 -493 000 -335 000 -557 000
othertotalStockholdersEquity 820M 816M 812M 807M 803M 798M 794M 789M 782M 774M
totalStockholdersEquity 176M 195M 206M 226M 234M 297M 311M 364M 411M 458M
totalEquity 176M 195M 206M 226M 234M 297M 311M 364M 411M 458M
totalLiabilitiesAndStockholdersEquity 273M 294M 306M 326M 340M 408M 427M 482M 533M 569M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 273M 294M 306M 326M 340M 408M 427M 482M 533M 569M
totalInvestments 116M 146M 156M 164M 174M 180M 196M 217M 262M 0
totalDebt 85M 86M 86M 86M 86M 87M 83M 80M 71M 57M
netDebt 79M 79M 80M 75M 77M 65M 56M 36M 30M 15M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol TIL TIL TIL TIL TIL TIL TIL TIL TIL TIL
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-08-13 2024-05-10 2024-03-21 2023-11-13 2023-08-14 2023-05-11 2023-03-31 2022-11-14 2022-08-12
acceptedDate 2024-11-13 07:39:58 2024-08-13 17:16:42 2024-05-10 07:10:33 2024-03-21 17:05:50 2023-11-13 17:03:23 2023-08-14 07:05:14 2023-05-11 07:09:31 2023-03-31 07:38:45 2022-11-14 16:17:06 2022-08-12 07:23:11
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -23M -15M -24M -13M -67M -19M -57M -54M -56M -59M
depreciationAndAmortization 901 000 975 000 993 000 1M 953 000 991 000 2M 2M 2M 1M
deferredIncomeTax 0 0 0 -7M 45M -2M 0 0 0 0
stockBasedCompensation 4M 4M 5M 5M 5M 4M 5M 7M 8M 8M
changeInWorkingCapital -9M -1M 2M -1M 1M -5M -4M -6M 5M 1M
accountsReceivables 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0
accountsPayables -45 000 -9000 20 000 -477 000 -425 000 753 000 -980 000 -2M -232 000 4M
otherWorkingCapital -9M -1M 2M -574 000 2M -6M 980 000 -3M 5M 0
otherNonCashItems 7M 179 999 9M 2M 668 000 1M 20M 14M 754 000 1M
netCashProvidedByOperatingActivities -20M -11M -14M -13M -14M -20M -35M -37M -41M -47M
investmentsInPropertyPlantAndEquipment 0 0 0 -58 000 -5M -7M -8M -13M -25M -26M
acquisitionsNet -541 000 541 000 0 0 0 0 0 1M 0 0
purchasesOfInvestments -16M -40M -51M -51M -72M -96M -82M -109M -84M -221M
salesMaturitiesOfInvestments 47M 52M 60M 63M 80M 114M 105M 154M 135M 226M
otherInvestingActivites -11M 0 0 2M 0 0 0 -1M 0 0
netCashUsedForInvestingActivites 20M 12M 9M 14M 2M 10M 15M 33M 25M -22M
debtRepayment 0 0 0 -587 000 -587 000 -4M 0 0 0 0
commonStockIssued 0 0 0 0 0 0 0 2M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 159 000 0 0 587 000 -587 000 8M 4M 5M 15M 51M
netCashUsedProvidedByFinancingActivities 159 000 0 0 1M -587 000 4M 4M 6M 15M 51M
effectOfForexChangesOnCash 42 000 -8000 -63 000 -19 000 -85 000 -73 000 -24 000 70 000 -563 000 -873 000
netChangeInCash -118 000 1M -5M 2M -13M -5M -16M 2M -1M -19M
cashAtEndOfPeriod 7M 7M 5M 11M 10M 23M 28M 44M 42M 43M
cashAtBeginningOfPeriod 7M 5M 11M 9M 23M 28M 44M 42M 43M 62M
operatingCashFlow -20M -11M -14M -13M -14M -20M -35M -37M -41M -47M
capitalExpenditure 0 0 0 -58 000 -5M -7M -8M -13M -25M -26M
freeCashFlow -20M -11M -14M -13M -20M -27M -43M -50M -66M -73M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-03-21 21:00 ET
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-01-16 13:00 ET
Instil Bio Announces Strategic Update
2023-12-05 22:00 ET
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
2023-11-13 22:00 ET
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-11-06 12:00 ET
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
2023-08-14 11:00 ET
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-06-26 20:38 ET
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
2023-05-11 11:00 ET
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-03-31 11:00 ET
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2023-01-31 22:00 ET
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
2023-01-09 12:00 ET
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
2022-12-12 16:45 ET
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
2022-12-08 12:00 ET
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
2022-11-14 21:07 ET
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-11-08 12:00 ET
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-10-31 11:00 ET
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
2022-10-18 11:00 ET
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
2022-09-19 11:20 ET
Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
2022-09-09 11:00 ET
Instil Bio to Present at Morgan Stanley Global Healthcare Conference
2022-09-06 11:00 ET
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer
2022-08-12 11:00 ET
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-05-27 11:00 ET
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
2022-05-18 11:00 ET
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
2022-05-16 11:00 ET
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-03-07 12:00 ET
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2022-03-02 12:00 ET
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
2021-11-15 12:00 ET
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-11-15 12:00 ET
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-08 13:05 ET
Instil Bio to Present at Upcoming Investor Conferences in November
2021-09-16 11:00 ET
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
2021-09-13 11:00 ET
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
2021-09-02 11:00 ET
Instil Bio to Present at Upcoming Investor Conferences in September
2021-08-12 11:00 ET
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-06-01 11:00 ET
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
2021-05-13 11:00 ET
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-04-27 11:00 ET
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
2021-04-12 11:18 ET
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
2021-03-23 21:00 ET
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-03-19 00:26 ET
Instil Bio Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2025-05-27 21:03 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-27 21:03 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-22 10:02 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-22 10:02 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 10
2025-05-13 11:06 ET
Instil Bio, Inc. reported for 2025 q1
SEC form 8
2025-05-13 00:00 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 8
2025-05-13 00:00 ET
Instil Bio, Inc. published news for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Instil Bio, Inc. reported for 2025 q1
SEC form 8
2025-03-28 21:38 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-28 21:38 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-28 21:38 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 10
2025-03-04 12:42 ET
Instil Bio, Inc. reported for 2024 q4
SEC form 8
2025-03-04 00:00 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Instil Bio, Inc. reported for 2024 q4
SEC form 8
2025-03-04 00:00 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 8
2025-03-04 00:00 ET
Instil Bio, Inc. published news for 2024 q4
SEC form 10
2024-11-13 07:39 ET
Instil Bio, Inc. reported for 2024 q3
SEC form 8
2024-11-13 07:01 ET
Instil Bio, Inc. published news for 2024 q3
SEC form 8
2024-11-13 07:01 ET
Instil Bio, Inc. published news for 2024 q3
SEC form 10
2024-11-13 00:00 ET
Instil Bio, Inc. reported for 2024 q3
SEC form 8
2024-08-13 00:00 ET
Instil Bio, Inc. published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Instil Bio, Inc. published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Instil Bio, Inc. reported for 2024 q2
SEC form 8
2024-05-10 00:00 ET
Instil Bio, Inc. published news for 2024 q1
SEC form 10
2024-05-10 00:00 ET
Instil Bio, Inc. reported for 2024 q1
SEC form 8
2024-05-10 00:00 ET
Instil Bio, Inc. published news for 2024 q1
SEC form 10
2024-03-21 00:00 ET
Instil Bio, Inc. reported for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Instil Bio, Inc. published news for 2023 q4
SEC form 8
2024-03-21 00:00 ET
Instil Bio, Inc. published news for 2023 q4
SEC form 10
2023-11-13 17:03 ET
Instil Bio, Inc. reported for 2023 q3
SEC form 8
2023-11-13 17:00 ET
Instil Bio, Inc. published news for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Instil Bio, Inc. reported for 2023 q3
SEC form 10
2023-08-14 07:05 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 6
2023-08-14 07:01 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Instil Bio, Inc. reported for 2023 q2
SEC form 6
2023-06-26 16:32 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 6
2023-06-14 16:31 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 10
2023-05-11 07:09 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 6
2023-05-11 07:05 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Instil Bio, Inc. reported for 2023 q1
SEC form 6
2023-04-24 16:30 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 6
2023-04-14 16:29 ET
Instil Bio, Inc. published news for 2023 q1
SEC form 10
2023-03-31 07:38 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 6
2023-03-31 07:07 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 8
2023-03-31 00:00 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 10
2023-03-31 00:00 ET
Instil Bio, Inc. reported for 2022 q4
SEC form 6
2023-03-10 15:47 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-02-27 17:06 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-02-01 17:01 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-01-27 17:00 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2023-01-09 16:00 ET
Instil Bio, Inc. published news for 2022 q4
SEC form 6
2022-12-08 17:00 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 10
2022-11-14 16:17 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 6
2022-11-14 16:05 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Instil Bio, Inc. reported for 2022 q3
SEC form 6
2022-11-08 16:35 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 6
2022-10-31 07:24 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 6
2022-10-18 17:01 ET
Instil Bio, Inc. published news for 2022 q3
SEC form 6
2022-09-06 17:41 ET
Instil Bio, Inc. published news for 2022 q2
SEC form 6
2022-09-06 17:23 ET
Instil Bio, Inc. published news for 2022 q2
SEC form 6
2022-09-06 17:00 ET
Instil Bio, Inc. published news for 2022 q2
SEC form 10
2022-08-12 07:23 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 6
2022-08-12 07:03 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 10
2022-08-12 00:00 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 8
2022-08-12 00:00 ET
Instil Bio, Inc. reported for 2022 q2
SEC form 6
2022-06-13 17:08 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-27 17:02 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-20 17:08 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-18 17:03 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-05-16 07:13 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 10
2022-05-16 07:03 ET
Instil Bio, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Instil Bio, Inc. reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Instil Bio, Inc. reported for 2022 q1
SEC form 6
2022-05-03 17:01 ET
Instil Bio, Inc. published news for 2022 q1
SEC form 6
2022-03-30 16:20 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 10
2022-03-07 07:14 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 6
2022-03-07 07:05 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 8
2022-03-07 00:00 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 10
2022-03-07 00:00 ET
Instil Bio, Inc. published news for 2021 q4
SEC form 6
2021-12-17 17:00 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-15 07:19 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 10
2021-11-15 07:16 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 6
2021-11-15 07:10 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Instil Bio, Inc. published news for 2021 q3
SEC form 6
2021-09-16 07:11 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 6
2021-09-13 16:02 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 10
2021-08-12 16:04 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 6
2021-08-12 16:00 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Instil Bio, Inc. published news for 2021 q2
SEC form 6
2021-05-13 16:40 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 10
2021-05-13 16:38 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 6
2021-04-27 17:23 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 6
2021-04-13 16:48 ET
Instil Bio, Inc. published news for 2021 q1
SEC form 6
2021-03-23 16:22 ET
Instil Bio, Inc. published news for 2020 q4